Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells.

Yi H, Cho HJ, Cho SM, Jo K, Park JA, Lee SH, Chang BJ, Kim JS, Shin HC.

Korean J Physiol Pharmacol. 2012 Feb;16(1):11-6. doi: 10.4196/kjpp.2012.16.1.11. Epub 2012 Feb 28.


Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.

Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim NH, Amidon GL, Kim JS, Shin HC.

Int J Oncol. 2012 Jul;41(1):310-6. doi: 10.3892/ijo.2012.1447. Epub 2012 Apr 26.


IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation.

Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, Wang X, Keng P, Lee SO.

Radiat Oncol. 2015 Nov 14;10:227. doi: 10.1186/s13014-015-0534-1.


Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.

Jiang Y, He Y, Li H, Li HN, Zhang L, Hu W, Sun YM, Chen FL, Jin XM.

Gastric Cancer. 2012 Oct;15(4):440-50. doi: 10.1007/s10120-012-0140-y. Epub 2012 Feb 14.


Detection of tumor stem cell markers in pancreatic carcinoma cell lines.

Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H.

Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):92-7.


Chemoresistance of CD133(+) colon cancer may be related with increased survivin expression.

Lee MR, Ji SY, Mia-Jan K, Cho MY.

Biochem Biophys Res Commun. 2015 Jul 31;463(3):229-34. doi: 10.1016/j.bbrc.2015.05.031. Epub 2015 May 20.


Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.

Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N.

Oncol Rep. 2012 Oct;28(4):1301-8. doi: 10.3892/or.2012.1951. Epub 2012 Aug 6.


Functional expression and characterization in Xenopus laevis oocytes of the ABCG2 transporter derived from A549 human lung adenocarcinoma cells.

Lee DG, Cho HJ, Yi H, Cho SM, Jo K, Park JA, Lee BH, Hwang SH, Jeong SM, Nah SY, Shin HC.

Oncol Rep. 2012 Feb;27(2):499-503. doi: 10.3892/or.2011.1490. Epub 2011 Oct 4.


The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.

Li F, Zeng H, Ying K.

Med Oncol. 2011 Dec;28(4):1458-62. doi: 10.1007/s12032-010-9646-5. Epub 2010 Aug 18.


Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.

Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G.

Int J Oncol. 2010 Aug;37(2):437-44.


Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.

Bessho Y, Oguri T, Achiwa H, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R.

Cancer Sci. 2006 Mar;97(3):192-8.


Multilevel regulation of IL-6R by IL-6-sIL-6R fusion protein according to the primitiveness of peripheral blood-derived CD133+ cells.

Campard D, Vasse M, Rose-John S, Poyer F, Lamacz M, Vannier JP.

Stem Cells. 2006 May;24(5):1302-14. Epub 2005 Dec 15.


Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer.

Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee K, Park JJ, Pil Hong S, Cheon JH, Kim TI, Kim WH.

Int J Cancer. 2014 Feb 1;134(3):519-29. doi: 10.1002/ijc.28381. Epub 2013 Aug 7.


The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.

Ying J, Tsujii M, Kondo J, Hayashi Y, Kato M, Akasaka T, Inoue T, Shiraishi E, Inoue T, Hiyama S, Tsujii Y, Maekawa A, Kawai S, Fujinaga T, Araki M, Shinzaki S, Watabe K, Nishida T, Iijima H, Takehara T.

Int J Oncol. 2015 Apr;46(4):1551-9. doi: 10.3892/ijo.2015.2851. Epub 2015 Jan 26.


Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.

Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH.

Cancer. 2011 Jul 1;117(13):2970-85. doi: 10.1002/cncr.25869. Epub 2011 Jan 10.


Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.

Hang D, Dong HC, Ning T, Dong B, Hou DL, Xu WG.

Dis Esophagus. 2012 Sep-Oct;25(7):638-44. doi: 10.1111/j.1442-2050.2011.01298.x. Epub 2012 Jan 11.


Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays.

Warrier S, Pavanram P, Raina D, Arvind M.

Cell Biol Int. 2012;36(12):1137-43. doi: 10.1042/CBI20110539.


CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype.

Paschall AV, Yang D, Lu C, Redd PS, Choi JH, Heaton CM, Lee JR, Nayak-Kapoor A, Liu K.

Oncotarget. 2016 Nov 29;7(48):78698-78712. doi: 10.18632/oncotarget.12168.


Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.

Ganapathi MK, Weizer AK, Borsellino S, Bukowski RM, Ganapathi R, Rice T, Casey G, Kawamura K.

Cell Growth Differ. 1996 Jul;7(7):923-9.


Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.

Kim NH, Kim SK, Kim DS, Zhang D, Park JA, Yi H, Kim JS, Shin HC.

Oncol Lett. 2015 May;9(5):2283-2288. Epub 2015 Mar 9.

Supplemental Content

Support Center